Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting of the Leukemia Stem Cell Population With Arsenic Trioxide and Tyrosine Kinase Inhibitors for CML

NCT01397734 is registered in ClinicalTrials.gov with Beth Israel Deaconess Medical Center as lead sponsor.

NCT NCT01397734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01397734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting of the Leukemia Stem Cell Population With Arsenic Trioxide and Tyrosine Kinase Inhibitors for CML
Lead sponsor
Beth Israel Deaconess Medical Center
Phase
Phase 1
Overall status
Terminated
Start date
September 30, 2011
Completion date
August 6, 2018
Enrollment
7 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelogenous leukemia